This poster, presented at theĀ Gordon Research Conference in August 2017, concluded that:
- Provide expert assessment and interpretation of literature and available databases and are invaluable in identifying and avoiding target-related risks
- Inform target selection and/or prioritisation early in discovery
- Should contain the level of detail appropriate to the project stage
- Should combine with emerging nonclinical and clinical data to build a picture that mitigates and manages risks at later stages in the project
Read more here:Ā Ā Target Safety Assessments and Their Role in de-risking drug discovery: Nav1.7 as an example. Claire Sadler, Lauren Eades, Richard Knight, Michael Morton and Ruth Roberts.